Pancreatic Cancer Research

ResearcherIpsen (United States)Active in the last 2 years

Paul C. Cockrum

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111416419. Sources: OpenAlex.

Their work

Papers
15 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2020: 2 papers · 2021: 5 papers · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 15

  1. Real-world clinical outcomes and economic burden of metastatic pancreatic ductal adenocarcinoma: a systematic review. Co-author DOI 10.1080/14796694.2024.2435253↗
  2. Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.36469/001c.142403↗
  3. The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.36469/001c.124367↗
  4. Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1002/cam4.5714↗
  5. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. First author DOI 10.1080/03007995.2022.2059976↗
  6. Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma. First author DOI 10.1093/oncolo/oyac028↗
  7. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States. Last author DOI 10.1093/oncolo/oyac029↗
  8. Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community … Last author DOI 10.2147/ceor.s373316↗
  9. Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.4415↗
  10. Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.2217/fon-2020-0902↗
  11. Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan. Co-author DOI 10.3389/fonc.2021.678070↗
  12. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3389/fonc.2021.754687↗
  13. Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies. Co-author PMID 34267862↗
  14. Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes. First author DOI 10.1002/cam4.3477↗
  15. Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan. Co-author DOI 10.1177/1758835920944052↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. George Kim · 4 shared papers, 2020–2024 · strength 0.78
  2. Syvart Dennen · 2 shared papers, 2025 · strength 0.66
  3. Gabriela Dieguez · 3 shared papers, 2021–2024 · strength 0.65
  4. Kenneth H. Yu · 4 shared papers, 2020–2023 · strength 0.63
  5. Ravi Kumar Paluri · 2 shared papers, 2022–2025 · strength 0.51
  6. Samantha Tomicki · 2 shared papers, 2021–2022 · strength 0.37
  7. Eileen Mary O'Reilly · 2 shared papers, 2020–2023 · strength 0.35
  8. Bong Chul Chu · 2 shared papers, 2021–2022 · strength 0.34
  9. Ravi Paler · 1 shared paper, 2025 · strength 0.33
  10. Prachi Bhatt · 1 shared paper, 2024 · strength 0.28
  11. Zev A. Wainberg · 1 shared paper, 2022 · strength 0.20
  12. Armin Shahrokni · 1 shared paper, 2022 · strength 0.19
  13. Rawad Elias · 1 shared paper, 2022 · strength 0.19
  14. Ben George · 1 shared paper, 2021 · strength 0.17
  15. Bruce Belanger · 1 shared paper, 2021 · strength 0.16
  16. George P. Kim · 1 shared paper, 2021 · strength 0.16
  17. Laith I. Abushahin · 1 shared paper, 2021 · strength 0.16
  18. Jim M. Koeller · 1 shared paper, 2020 · strength 0.13
  19. Amber Draper · 1 shared paper, 2021 · strength 0.12
  20. Andrew Eugene Hendifar · 1 shared paper, 2021 · strength 0.12
  21. Maen Abdelrahim · 1 shared paper, 2021 · strength 0.12
  22. Ethan Alexander Burns · 1 shared paper, 2021 · strength 0.12
  23. Olatunji Boladale Alese · 1 shared paper, 2021 · strength 0.12
  24. Nathan Bahary · 1 shared paper, 2021 · strength 0.12
  25. Gazala Naaz Khan · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.